Two Additional Operations in Texas by 2027: GC Green Cross announced on the 14th that its U.S. subsidiary, ABO Holdings’ Calexico Plasma Center in California, has received approval from the U.S. Food and Drug Administration (FDA).
GC Green Cross successfully launched Alyglo in the U.S. market and acquired ABO Holdings in January this year to ensure long-term revenue growth. With this latest approval, all six plasma centers operated by ABO Holdings in the U.S. have now received FDA approval.
ABO Holdings plans to open two additional centers in Texas by 2027, bringing the total to eight plasma centers. In the U.S., FDA approval is essential to ensure the safety and quality of plasma collected at these centers. Once approved, the centers are authorized to sell the collected plasma.
Securing raw plasma supply is a crucial factor in the plasma fractionation business. All major global plasma fractionation companies, such as Australia’s CSL Behring, Japan’s Takeda, Spain’s Grifols, and Switzerland’s Octapharma, have their own plasma centers in the U.S.
Following this approval, ABO Holdings will generate revenue from its six plasma centers located in California, Utah, and New Jersey.
Heo Eun-cheol, CEO of GC Green Cross, stated, “We will secure stable revenue from Alyglo through our plasma centers operating in the U.S., which will significantly contribute to improving the company’s profitability.”